

Dusan Ruzic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2656351/publications.pdf>

Version: 2024-02-01

17
papers

238
citations

1163117

8
h-index

996975

15
g-index

21
all docs

21
docs citations

21
times ranked

309
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. <i>Pharmaceutics</i> , 2022, 14, 209.	4.5	26
2	Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions. <i>Journal of Molecular Structure</i> , 2022, 1257, 132621.	3.6	7
3	Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. <i>Future Medicinal Chemistry</i> , 2022, 14, 557-570.	2.3	0
4	Bistable Photoswitch Allows in Vivo Control of Hematopoiesis. <i>ACS Central Science</i> , 2022, 8, 57-66.	11.3	18
5	Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2571-2585.	5.4	5
6	<i>In silico</i> identification of novel 5-HT _{2A} antagonists supported with ligand- and target-based drug design methodologies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1819-1837.	3.5	12
7	Medicinal chemistry of histone deacetylase inhibitors. <i>Arhiv Za Farmaciju</i> , 2021, 71, 73-100.	0.5	2
8	Fragment-Based Drug Design of Selective HDAC6 Inhibitors. <i>Methods in Molecular Biology</i> , 2021, 2266, 155-170.	0.9	8
9	An Integrative <i>In silico</i> Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. <i>Molecular Informatics</i> , 2021, 40, e2000187.	2.5	7
10	Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods. <i>Letters in Drug Design and Discovery</i> , 2021, 18, .	0.7	0
11	Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein. <i>Molecules</i> , 2021, 26, 5300.	3.8	5
12	Structure-based design of selective histone deacetylase 6 zinc binding groups. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 3166-3177.	3.5	7
13	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 863-868.	2.8	6
14	Modulating Protein-Protein Interactions with Visible-Light-Responsive Peptide Backbone Photoswitches. <i>ChemBioChem</i> , 2019, 20, 1417-1429.	2.6	33
15	Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase 6 Inhibitors. <i>Molecular Informatics</i> , 2019, 38, e1800083.	2.5	17
16	In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. <i>Frontiers in Chemistry</i> , 2019, 7, 873.	3.6	71
17	Quantitative structure-retention relationship of selected imidazoline derivatives on Î±1-acid glycoprotein column. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 127, 101-111.	2.8	14